The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ties to healthcare and ...

Tesla stock rises sharply extending gains for a second day, Nvidia and Palantir shares trade higher as tech stocks bounce ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

Apollo Global Management, Novo Nordisk A/S, BlackRock, Blackstone, and Prologis are the five Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of ...

China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

A consortium consisting of Warburg Pincus and KKR are in talks to acquire German medical packaging maker Gerresheimer AG , ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...